Before taking Xagrid(Anagrelide)

This section highlights critical safety considerations for prescribers and patients.

Important Safety Considerations

A pre-treatment cardiovascular examination, including an ECG, is required due to risks of QT prolongation and tachycardia. Use is contraindicated in patients with severe hepatic impairment and requires a reduced dose in moderate impairment. Concomitant use with aspirin or other drugs affecting hemostasis increases bleeding risk and requires careful monitoring. Patients should be monitored for signs of pulmonary hypertension, pulmonary toxicity, and cardiovascular events. Breastfeeding is not recommended during therapy.